肿瘤患者化疗期间泮托拉唑致痛风复发的药学实践  

Pharmaceutical practice of proton pump inhibitors inducing gout recurrence in cancer patients on chemotherapy

作　　者：宋扬[1] 马岩[2] 高立娜[1] 王冬雪[1] 李馨[1] SONG Yang;MA Yan;GAO Lina;WANG Dongxue;LI Xin(Department of Pharmacy,Second Hospital of Jilin University,Jilin Changchun 130022,China;Department of Radiation Oncology,Second Hospital of Jilin University,Jilin Changchun 130022,China)

机构地区：[1]吉林大学第二医院药学部,吉林长春130022 [2]吉林大学第二医院放疗科,吉林长春130022

出　　处：《中国医院药学杂志》2024年第17期2066-2069,共4页Chinese Journal of Hospital Pharmacy

摘　　要：质子泵抑制剂(proton pump inhibitors,PPI)在临床应用的风险逐渐受到重视,目前关注焦点多在其可致药物相互作用。临床药师通过1例痛风史肺腺癌患者化疗期间使用泮托拉唑导致痛风复发的病例,系统评价了不良反应因果关系,总结了PPI导致痛风发作的机制,探讨了PPI致痛风发作的危险因素,制定了肿瘤患者使用PPI的个体化监护要点,通过调整抑酸药的品种,保障了患者化疗如期进行,充分体现了临床药师的临床价值。The risks of proton pump inhibitors(PPIs)in clinical applications have attracted a growing attention of clinicians.And current focus is placed upon on their potential for drug interactions.Clinical pharmacists systematically evaluated the causal relationship of adverse reactions,summarized the mechanisms and risk factors of PPI-induced gout attacks and developed personalized monitoring strategies for lung adenocarcinoma patients on chemotherapy.Through adjusting the variety of acid suppressants,chemotherapeutic cycles of cancer patients might proceed as scheduled,fully reflecting the clinical value of clinical pharmacists.

关 键 词：质子泵抑制剂 危险因素 痛风 肿瘤患者 药学监护 

分 类 号：R969.3[医药卫生—药理学]